USFDA inspections in India have accelerated recently, raising concerns about potential adverse observations. But industry insiders say today’s pharma firms are better positioned than a decade ago, thanks to tech upgrades and de-risking strategies. Analysts expect limited impact on earnings and stock prices, as companies can better cushion regulatory actions.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
